DexCom, Inc. (NASDAQ:DXCM) Shares Bought by EULAV Asset Management

EULAV Asset Management grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 8.0% in the third quarter, Holdings Channel reports. The institutional investor owned 81,000 shares of the medical device company’s stock after acquiring an additional 5,986 shares during the quarter. EULAV Asset Management’s holdings in DexCom were worth $5,430,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its position in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after acquiring an additional 6,544,102 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after purchasing an additional 435,401 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after purchasing an additional 345,114 shares during the last quarter. Finally, Bellevue Group AG raised its holdings in shares of DexCom by 33.5% in the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock valued at $169,380,000 after buying an additional 306,604 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DXCM has been the topic of several analyst reports. Robert W. Baird increased their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. UBS Group decreased their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Stifel Nicolaus increased their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Stock Performance

NASDAQ DXCM opened at $74.88 on Wednesday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The business’s 50-day moving average price is $70.29 and its 200 day moving average price is $90.44. The company has a market capitalization of $29.25 billion, a PE ratio of 44.84, a price-to-earnings-growth ratio of 2.33 and a beta of 1.17. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.